| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
Department of Endocrinology, 1 Department of Nuclear Medecine and 2 Department of Gastroenterology, Hôpital Rangueil, CHU Toulouse, TSA 50032, 31059 Toulouse-Cedex 9, France, 3 Laboratory of Histopathology, Centre Claudius Régaud, 24, Rue du Pont St Pierre, 31059 Toulouse-Cedex 9, France, 4 Laboratory of Histopathology and 5 Department of Surgery, Hôpital Purpan, CHU Toulouse, 31059 Toulouse-Cedex 9, France and 6 Institut National de la Santé et de la Recherche Médicale (Inserm) U531, IFR 31, Hôpital Rangueil, CHU Toulouse, TSA 50032, 31059 Toulouse-Cedex 9, France
(Correspondence should be addressed to P Caron; Email: caron.p{at}chu-toulouse.fr)
Objective: We studied the efficacy of octreotide treatment on hypoglycaemia in patients with insulinoma and its relationships with Octreoscan scintigraphy and the presence of tumoral somatostatin receptors sst2A and sst5.
Design and methods: 17 patients with insulinoma were evaluated using (i) evaluation of blood glucose, insulin and C-peptide during a short 100 µg octreotide test in fasting patients and/or treatment over 8 days–8 months with octreotide, (ii) Octreoscan scintigraphy and (iii) immunostaining of the tumor with anti-sst2A and anti-sst5.
Results: Octreotide was effective on hypoglycaemia in 10/17 patients. Octreoscan scintigraphy detected 4/17 insulinomas. sst2A receptor was detected in 7/17 insulinomas and sst5 in 15/17 insulinomas. Octreotide was effective on hypoglycaemia in those seven patients with sst2A receptor-expressing insulinoma, and in three patients with undetectable sst2A receptor and detectable sst5; it was ineffective in six patients whose tumor expressed the sst5 receptor with undetectable sst2A and in one patient with undetectable sst2A and sst5 receptor.
Conclusions: Octreotide is an effective treatment of hypoglycaemia in more than 50% of patients with insulinoma. Detection of responsive patients was better based on a positive short test with subcutaneous octreotide than on the results of Octreoscan scintigraphy. Positive anti-sst2 receptor immunostaining is associated with efficacy of octreotide treatment, but does not account for all cases of responsiveness to octreotide. Expression of sst5 receptor does not appear to explain per se the efficacy of octreotide on sst2A-negative insulinomas.
This article has been cited by other articles:
|
|
 |
|
  F. Ehehalt, H. D. Saeger, C. M. Schmidt, and R. Grutzmann Neuroendocrine Tumors of the Pancreas Oncologist, May 1, 2009; 14(5): 456 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, and A. B Grossman Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms Endocr. Relat. Cancer, September 1, 2008; 15(3): 701 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bhandari, N. Watson, E. Long, S. Sharpe, W. Zhong, S.-Z. Xu, and S. L. Atkin Expression of Somatostatin and Somatostatin Receptor Subtypes 1-5 in Human Normal and Diseased Kidney J. Histochem. Cytochem., August 1, 2008; 56(8): 733 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Asnacios, F. Courbon, P. Rochaix, E. Bauvin, V. Cances-Lauwers, C. Susini, S. Schulz, A. Boneu, R. Guimbaud, and L. Buscail Indium-111-Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors J. Clin. Oncol., February 20, 2008; 26(6): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cordelier, J.-P. Esteve, S. Najib, L. Moroder, N. Vaysse, L. Pradayrol, C. Susini, and L. Buscail Regulation of Neuronal Nitric-oxide Synthase Activity by Somatostatin Analogs following SST5 Somatostatin Receptor Activation J. Biol. Chem., July 14, 2006; 281(28): 19156 - 19171. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
